Neurological
Refine Search
Pharmaceutical
A survey of 4,000 patients in the USA and Europe has revealed their attitudes towards the non-profit groups supporting them and pharma companies, as well as how such organizations should work together. 14 August 2019
Pharmaceutical
Shares of Danish CNS specialist Lundbeck were up 3.3% at 269.60 Danish kroner by midday, despite revealing first-half financials showing that sales and earnings were down. 14 August 2019
Biotechnology
Ireland-headquartered Jazz Pharmaceuticals late Monday announced the acquisition of clinical-stage biotech firm Cavion, through a merger with a Jazz subsidiary. 13 August 2019
Biotechnology
Swiss biotech AC Immune has supplemented its research efforts in neurodegenerative diseases with a newly-announced partnership with the University of Pennsylvania (Penn). 12 August 2019
Generics
London-listed Jordanian drugmaker Hikma Pharmaceuticals today reported a strong set of interim results for the six months ended June 30, 2019, lifting the firm’s shares 6.98% to 1,969.50 pence by mid-morning. 9 August 2019
Pharmaceutical
The share price of Merck KGaA closed up 2.2% up on Thursday after the German company presented its second quarter financial results. 8 August 2019
Pharmaceutical
Edavarone, from Mitsubishi Tanabe Pharma, has been approved in China as an intravenous treatment for amyotrophic lateral sclerosis (ALS). 7 August 2019
Pharmaceutical
Hungary's largest drugmaker Gedeon Richter today posted financial results, showing that consolidated sales at 241,522 million forint ($819.5 million; 753.9 million euros), increasing 7.6% in forint terms and up 5.6% in euros during the first six months to June 2019 when compared with the first half of 2018. 6 August 2019
Biotechnology
US pharma major Eli Lilly has presented positive Phase III data on Emgality (galcanezumab-gnlm), a calcitonin gene-related peptide (CGRP) antagonist indicated in preventive treatment of migraine and for episodic cluster headache. 5 August 2019
Pharmaceutical
The global pharmaceutical industry has spent well over a trillion dollars on research and development in the last ten years, and analysts expect annual investment levels to grow by around 3% annually, reaching up to $200 billion per year by 2022. 5 August 2019
Pharmaceutical
Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the US Food and Drug Administration (FDA) to study patients’ experiences with pain and use of opioids. 1 August 2019
Pharmaceutical
Analzying Takeda’s latest quarterly financials is all about perspective, given that it is the first time that they include a full quarter of sales of products from Shire, the firm it acquired for $62 billion. 31 July 2019
Pharmaceutical
Sumitomo Dainippon Pharma has at last submitted a new drug application for approval of manufacturing and marketing for lurasidone hydrochloride in Japan for the treatment of schizophrenia and bipolar depression. 31 July 2019
Pharmaceutical
Sunovion Pharmaceuticals, a subsidiary of Japan's Sumitomo Dainippon, has announced that the US regulator will review its novel treatment option dasotraline, for moderate-to-severe binge eating disorder (BED). 30 July 2019
Biotechnology
Positive top-line results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase III study of Vumerity (diroximel fumarate), an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to Biogen’s Tecfidera (dimethyl fumarate) were released today. 30 July 2019
Generics
Israel’s Teva Pharmaceutical Industries, the USA’s Endo Pharmaceuticals and Japanese drugmaker Teikoku Pharma will pay $70 million and have agreed to temporarily avoid pay-for-delay deals to end allegations they illegally delayed cheaper alternatives to the narcolepsy drug Provigil (modafinil) and the pain treatment Lidoderm (lidocaine), California’s Attorney General said Monday, according to media reports. 30 July 2019
Pharmaceutical
Last week’s news included a setback for Biohaven Pharmaceuticals, with the US Food and Drug Administration issuing a CRL for its amyotrophic lateral sclerosis drug Nurtec. Research news of note was Acadia presenting new Phase III data on its schizophrenia candidate Nuplazid (pimavanserin) that failed to impress, and Intec Pharma last Monday releasing Phase III data in its Accordion-Pill-Carbidopa/Levodopa showing that it was not superior to Sinemet. On the government affairs front, last Tuesday saw the US Senate Finance Committee release details of the long-awaited proposed legislation on pharma pricing which has come in for much scrutiny. 28 July 2019
Pharmaceutical
Following its July 22-25 meetings, today the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended four novel medicines for approval. 26 July 2019
Generics
London-listed Jordanian drugmaker Hikma Pharmaceuticals and Hungary’s biggest pharma firm Gedeon Richter today announced the signing of an exclusive license agreement to commercialize cariprazine, a novel antipsychotic, in certain Middle East and North African (MENA) markets. 25 July 2019
Biotechnology
Maryland, USA-based gene therapy specialist Regenxbio has signed a deal with Swiss immunotherapy firm Neurimmune to develop novel AAV gene therapies. 25 July 2019
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Sage Therapeutics will down tools on its dalzanemdor program, after the Phase II DIMENSION trial missed both primary and secondary endpoints. 21 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November meeting, notable among which was a reversal of a previous rejection of Alzheimer’s drug Leqembi (lecanemab). 15 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Biotechnology
Swiss clinical-stage biopharma AC Immune saw its shares gain 8% to $3.38 in US trading this morning, after it released positive interim safety and immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056. 14 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the treatment of AADC (aromatic L-amino acid decarboxylase) deficiency, making it the first-ever gene therapy approved in the USA that is directly administered to the brain. 14 November 2024
Pharmaceutical
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm MEDICE Arzneimittel Pütter. 14 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Pharmaceutical
US drugmaker AbbVie was trading more than 11% lower early on Monday afternoon in New York. 11 November 2024
Pharmaceutical
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research.. 11 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze